Waverley Pharma Inc.

Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.